Strategies to Reduce HCV Incidence in Key Populations: The Role of HCV Treatment as Prevention

This interactive multimedia module, designed for healthcare providers in Europe, highlights treatment as prevention as a strategy to reduce HCV incidence in persons who inject drugs.

Graham R. Foster, FRCP, PhD
Program Director Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: March 27, 2019 Expired: No longer available for credit

Who Should Be Treated for HCV? (5 mins)

Why Should PWID Be Treated? (10 mins)

How Should PWID Be Treated? (32 mins)

This downloadable slideset reviews the importance of treatment as prevention in achievement of HCV elimination goals in Europe and provides practical strategies for implementing treatment and support services in PWID and those in the correctional setting.

Graham R. Foster, FRCP, PhD
Program Director Released: March 27, 2019

Now that clinicians outside of hospital settings can assess and treat HCV in France, which high-risk groups should we target for HCV “microelimination” and how? Here’s my take.

Karine Lacombe, MD, PhD Released: April 23, 2019

HCV prevalence remains high among PWID and incarcerated individuals in Germany, as barriers to care persist. How can we best provide both HCV treatment and harm reduction services to these key populations? Here’s my take.

Heiner Wedemeyer, MD Released: May 17, 2019

Spain has the highest HCV treatment rate among European nations, yet challenges remain for our goal of eliminating HCV by 2030. Read my take on how we should best implement national strategies at the local level in high-priority populations.

Marta Torrens, MD Released: July 5, 2019

Outdated regulatory barriers stand in the way of ready access to DAA therapy in Italy. How can we best reform these policies (eg, complex pretreatment characterization, prescriber restrictions) to treat more PWID and move closer to HCV elimination? Here’s my take.

Alessio Aghemo, MD, PhD Released: August 2, 2019

The promising HCV treatment as prevention (TasP) model has yet to be proven in real-world PWID. Here, we share our experiences, progress, and remaining challenges with evaluating a local HCV TasP program in Tayside, Scotland.

Christopher Byrne, BA (Hons), MSc John F. Dillon, MB BS, MRCP, MD, FRCP (Edin), FRCP (Lond) Released: September 4, 2019

This on-demand audio features expert perspectives on HCV elimination efforts in France and the UK and highlights globally applicable lessons on treatment as prevention.

Graham R. Foster, FRCP, PhD
Program Director Karine Lacombe, MD, PhD Released: May 8, 2019

This on-demand audio features expert perspectives on HCV elimination efforts in Germany and the UK and highlights globally applicable lessons on treatment as prevention.

Graham R. Foster, FRCP, PhD
Program Director Heiner Wedemeyer, MD Released: May 14, 2019

This on-demand audio features expert perspectives on HCV elimination efforts in Italy and Spain and highlights globally applicable lessons on treatment as prevention.

Alessio Aghemo, MD, PhD Marta Torrens, MD Released: June 3, 2019

This on-demand audio features expert perspectives on HCV elimination efforts in Italy and France and highlights globally applicable lessons on treatment as prevention.

Alessio Aghemo, MD, PhD Karine Lacombe, MD, PhD Released: August 27, 2019